Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials. Therapeutic options in response to the...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2020-03, Vol.19 (3), p.149-150 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 150 |
|---|---|
| container_issue | 3 |
| container_start_page | 149 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 19 |
| creator | Li, Guangdi De Clercq, Erik |
| description | Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials. |
| doi_str_mv | 10.1038/d41573-020-00016-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2475007000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A616202889</galeid><sourcerecordid>A616202889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-fe855ddbcbfb43595cfe46ebcc7e6430dfe201a8bf67fc5d627166e58de56d843</originalsourceid><addsrcrecordid>eNp9kUtLAzEUhYMotj7-gAsZcKOLqUkmr24EKb6g4Ka6DTPJTZ3STmoyI_jvTW1tEUSySLj5zsnNPQidETwguFDXlhEuixxTnGOMicjxHuoTJllOpGL727MUPXQU42zFEEkPUa-ghEohRB_dTN4glEvo2tpkftnWvomZ8yFr3yCjmAyzxn_APDM--Kb8qEMXs8tVPW9G_vXqBB24ch7hdLMfo5f7u8noMR8_PzyNbse54Qq3uQPFubWVqVzFCj7kxgETUBkjQbACWwfJs1SVE9IZbgWVRAjgygIXVrHiGF2sfZfBv3cQWz3zXWjSk5oyyTGWaQI7alrOQdeN820ozaKORt8KIiimSg0TNfiDSsvCoja-AVen-i8BXQtM8DEGcHoZ6kUZPjXBepWEXiehUxL6Owm96uV803FXLcBuJT-jT0CxBmK6aqYQdl_6x_YL2KKP3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475007000</pqid></control><display><type>article</type><title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Li, Guangdi ; De Clercq, Erik</creator><creatorcontrib>Li, Guangdi ; De Clercq, Erik</creatorcontrib><description>Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/d41573-020-00016-0</identifier><identifier>PMID: 32127666</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenosine Monophosphate - analogs & derivatives ; Adenosine Monophosphate - therapeutic use ; Alanine - analogs & derivatives ; Alanine - therapeutic use ; Antiviral agents ; Antiviral Agents - therapeutic use ; Betacoronavirus - drug effects ; Betacoronavirus - genetics ; Betacoronavirus - pathogenicity ; Clinical trials ; Comment ; Coronavirus Infections - drug therapy ; Coronaviruses ; COVID-19 ; Drug Repositioning ; Drug targeting ; Genetic aspects ; Hepatitis B - drug therapy ; Hepatitis C - drug therapy ; HIV Infections - drug therapy ; Humans ; Influenza, Human - drug therapy ; Interferon-alpha - pharmacology ; Interferon-alpha - therapeutic use ; Middle East Respiratory Syndrome Coronavirus - drug effects ; Middle East Respiratory Syndrome Coronavirus - genetics ; Middle East Respiratory Syndrome Coronavirus - pathogenicity ; Nucleosides - pharmacology ; Nucleosides - therapeutic use ; Pharmacology, Experimental ; Physiological aspects ; Pneumonia, Viral - drug therapy ; Polyethylene Glycols - pharmacology ; Polyethylene Glycols - therapeutic use ; Protease Inhibitors - pharmacology ; Protease Inhibitors - therapeutic use ; Recombinant Proteins - pharmacology ; Recombinant Proteins - therapeutic use ; SARS Virus - drug effects ; SARS Virus - genetics ; SARS Virus - pathogenicity ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus - drug effects</subject><ispartof>Nature reviews. Drug discovery, 2020-03, Vol.19 (3), p.149-150</ispartof><rights>Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-fe855ddbcbfb43595cfe46ebcc7e6430dfe201a8bf67fc5d627166e58de56d843</citedby><cites>FETCH-LOGICAL-c580t-fe855ddbcbfb43595cfe46ebcc7e6430dfe201a8bf67fc5d627166e58de56d843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32127666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Guangdi</creatorcontrib><creatorcontrib>De Clercq, Erik</creatorcontrib><title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><description>Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.</description><subject>Adenosine Monophosphate - analogs & derivatives</subject><subject>Adenosine Monophosphate - therapeutic use</subject><subject>Alanine - analogs & derivatives</subject><subject>Alanine - therapeutic use</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus - drug effects</subject><subject>Betacoronavirus - genetics</subject><subject>Betacoronavirus - pathogenicity</subject><subject>Clinical trials</subject><subject>Comment</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug Repositioning</subject><subject>Drug targeting</subject><subject>Genetic aspects</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis C - drug therapy</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Influenza, Human - drug therapy</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Middle East Respiratory Syndrome Coronavirus - drug effects</subject><subject>Middle East Respiratory Syndrome Coronavirus - genetics</subject><subject>Middle East Respiratory Syndrome Coronavirus - pathogenicity</subject><subject>Nucleosides - pharmacology</subject><subject>Nucleosides - therapeutic use</subject><subject>Pharmacology, Experimental</subject><subject>Physiological aspects</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Polyethylene Glycols - pharmacology</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Protease Inhibitors - pharmacology</subject><subject>Protease Inhibitors - therapeutic use</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>SARS Virus - drug effects</subject><subject>SARS Virus - genetics</subject><subject>SARS Virus - pathogenicity</subject><subject>SARS-CoV-2</subject><subject>Spike Glycoprotein, Coronavirus - drug effects</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtLAzEUhYMotj7-gAsZcKOLqUkmr24EKb6g4Ka6DTPJTZ3STmoyI_jvTW1tEUSySLj5zsnNPQidETwguFDXlhEuixxTnGOMicjxHuoTJllOpGL727MUPXQU42zFEEkPUa-ghEohRB_dTN4glEvo2tpkftnWvomZ8yFr3yCjmAyzxn_APDM--Kb8qEMXs8tVPW9G_vXqBB24ch7hdLMfo5f7u8noMR8_PzyNbse54Qq3uQPFubWVqVzFCj7kxgETUBkjQbACWwfJs1SVE9IZbgWVRAjgygIXVrHiGF2sfZfBv3cQWz3zXWjSk5oyyTGWaQI7alrOQdeN820ozaKORt8KIiimSg0TNfiDSsvCoja-AVen-i8BXQtM8DEGcHoZ6kUZPjXBepWEXiehUxL6Owm96uV803FXLcBuJT-jT0CxBmK6aqYQdl_6x_YL2KKP3g</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Li, Guangdi</creator><creator>De Clercq, Erik</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200301</creationdate><title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</title><author>Li, Guangdi ; De Clercq, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-fe855ddbcbfb43595cfe46ebcc7e6430dfe201a8bf67fc5d627166e58de56d843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine Monophosphate - analogs & derivatives</topic><topic>Adenosine Monophosphate - therapeutic use</topic><topic>Alanine - analogs & derivatives</topic><topic>Alanine - therapeutic use</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus - drug effects</topic><topic>Betacoronavirus - genetics</topic><topic>Betacoronavirus - pathogenicity</topic><topic>Clinical trials</topic><topic>Comment</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug Repositioning</topic><topic>Drug targeting</topic><topic>Genetic aspects</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis C - drug therapy</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Influenza, Human - drug therapy</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Middle East Respiratory Syndrome Coronavirus - drug effects</topic><topic>Middle East Respiratory Syndrome Coronavirus - genetics</topic><topic>Middle East Respiratory Syndrome Coronavirus - pathogenicity</topic><topic>Nucleosides - pharmacology</topic><topic>Nucleosides - therapeutic use</topic><topic>Pharmacology, Experimental</topic><topic>Physiological aspects</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Polyethylene Glycols - pharmacology</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Protease Inhibitors - pharmacology</topic><topic>Protease Inhibitors - therapeutic use</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>SARS Virus - drug effects</topic><topic>SARS Virus - genetics</topic><topic>SARS Virus - pathogenicity</topic><topic>SARS-CoV-2</topic><topic>Spike Glycoprotein, Coronavirus - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Guangdi</creatorcontrib><creatorcontrib>De Clercq, Erik</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Guangdi</au><au>De Clercq, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>19</volume><issue>3</issue><spage>149</spage><epage>150</epage><pages>149-150</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32127666</pmid><doi>10.1038/d41573-020-00016-0</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2020-03, Vol.19 (3), p.149-150 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_journals_2475007000 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - analogs & derivatives Alanine - therapeutic use Antiviral agents Antiviral Agents - therapeutic use Betacoronavirus - drug effects Betacoronavirus - genetics Betacoronavirus - pathogenicity Clinical trials Comment Coronavirus Infections - drug therapy Coronaviruses COVID-19 Drug Repositioning Drug targeting Genetic aspects Hepatitis B - drug therapy Hepatitis C - drug therapy HIV Infections - drug therapy Humans Influenza, Human - drug therapy Interferon-alpha - pharmacology Interferon-alpha - therapeutic use Middle East Respiratory Syndrome Coronavirus - drug effects Middle East Respiratory Syndrome Coronavirus - genetics Middle East Respiratory Syndrome Coronavirus - pathogenicity Nucleosides - pharmacology Nucleosides - therapeutic use Pharmacology, Experimental Physiological aspects Pneumonia, Viral - drug therapy Polyethylene Glycols - pharmacology Polyethylene Glycols - therapeutic use Protease Inhibitors - pharmacology Protease Inhibitors - therapeutic use Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use SARS Virus - drug effects SARS Virus - genetics SARS Virus - pathogenicity SARS-CoV-2 Spike Glycoprotein, Coronavirus - drug effects |
| title | Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A17%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20options%20for%20the%202019%20novel%20coronavirus%20(2019-nCoV)&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Li,%20Guangdi&rft.date=2020-03-01&rft.volume=19&rft.issue=3&rft.spage=149&rft.epage=150&rft.pages=149-150&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/d41573-020-00016-0&rft_dat=%3Cgale_proqu%3EA616202889%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475007000&rft_id=info:pmid/32127666&rft_galeid=A616202889&rfr_iscdi=true |